FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
FDA approves Vertex's non-opioid painkiller, first new kind of pain medicine in decades
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
Life Science Washington Welcomes New Board Members as the State’s Life Sciences Industry Strengthens Its Position as a Top 10 US Cluster
Life Science Washington, the state’s life sciences industry association, today announced the expansion of its board of directors with the addition of nine new members, representing distinguished ...
India Today on MSN14h
Vertex: New non-opioid painkiller Journavx approved by FDA
The FDA approved Vertex Pharmaceuticals’ Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...
Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’
We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...
FDA approves drug from Boston-based company to treat pain without opioid effects
The drug, suzetrigine, made by Boston-based Vertex Pharmaceuticals and to be sold as Journavx, works only on nerves outside ...
The Washington Post18d
Billed as nonaddictive, new pain pill could soon win FDA approval
If successful, the drug developed by Vertex Pharmaceuticals would offer a ... at the Center for Pain Relief at the University of Washington Medical Center-Roosevelt. “It’s a fantasy to think ...
Evercore ISI Sticks to Their Buy Rating for Madrigal Pharmaceuticals (MDGL)
In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report), with a ...